Precigen (PGEN) Net Cash Flow (2012 - 2026)
Precigen (PGEN) posted quarterly Net Cash Flow of -$22.8 million for Q1 2026, up 3.03% year-over-year from -$22.1 million in Q1 2025, and down 243.16% quarter-over-quarter from $15.9 million in Q4 2025.
Precigen (PGEN) Net Cash Flow (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Net Cash Flow for 15 consecutive years, with -$22.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 3.03% year-over-year to -$22.8 million; the TTM figure through Mar 2026 stood at $1.4 million (up 111.88% YoY), while the FY2025 annual figure was $682000.0, down 96.86% from the prior year.
- Net Cash Flow slipped to -$22.8 million in Q1 2026 per PGEN's latest filing, from $15.9 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $42.3 million in Q3 2022 and bottomed at -$43.3 million in Q4 2022.
- Historically, Net Cash Flow has averaged -$2.0 million across 5 years, with a median of -$2.4 million in 2022.
- On a YoY basis, Net Cash Flow climbed as much as 709.72% in 2022 and fell as far as 3616.83% in 2022.
- Precigen's Net Cash Flow stood at -$43.3 million in 2022, then jumped by 94.28% to -$2.5 million in 2023, then jumped by 293.85% to $4.8 million in 2024, then surged by 231.5% to $15.9 million in 2025, then plunged by 243.16% to -$22.8 million in 2026.
- Business Quant data shows PGEN's Net Cash Flow at -$22.8 million in Q1 2026, $15.9 million in Q4 2025, and $552000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Precigen | 2.18 Bn | 2.18 Bn | 52.17 Mn | 8.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.85 Mn |
| Jun 30, 2026 | 8.85 Mn |
| Mar 31, 2026 | -22.75 Mn |
| Mar 31, 2026 | -22.75 Mn |
| Dec 31, 2025 | 15.89 Mn |
| Dec 31, 2025 | 15.89 Mn |
| Sep 30, 2025 | 552,000.00 |
| Sep 30, 2025 | 552,000.00 |
| Jun 30, 2025 | 7.70 Mn |
| Jun 30, 2025 | 7.70 Mn |
| Mar 31, 2025 | -23.46 Mn |
| Mar 31, 2025 | -23.46 Mn |
| Dec 31, 2024 | 4.79 Mn |
| Dec 31, 2024 | 4.79 Mn |
| Sep 30, 2024 | 15.05 Mn |
| Sep 30, 2024 | 15.05 Mn |
| Jun 30, 2024 | -8.10 Mn |
| Jun 30, 2024 | -8.10 Mn |
| Mar 31, 2024 | 9.96 Mn |
| Mar 31, 2024 | 9.96 Mn |